Figure 1.
T-Stage and Nodal Involvement association with survival_
| Variable | Category | Alive | Death | p value |
|---|---|---|---|---|
| T Stage | Tumor invades lamina propria, muscularis mucosae, or submucosa (T1) | 0 (0.0%) | 1 (1.3%) | 0.967 |
| Tumor invades muscularis propria (T2) | 1 (25.0%) | 15 (19.7%) | ||
| Tumor invades adventitia (T3) | 2 (50.0%) | 46 (60.5%) | ||
| Tumor invades adjacent structures (T4) | 1 (25.0%) | 14 (18.4%) | ||
| Total | 4 (100.0%) | 76 (100.0%) | ||
| Nodal Involvement | No regional lymph node metastasis (N0) | 1 (25.0%) | 11 (14.5%) | 0.726 |
| Metastasis in 1–2 regional lymph nodes (N1) | 2 (50.0%) | 32 (42.1%) | ||
| Metastasis in 3–6 regional lymph nodes (N2) | 1 (25.0%) | 33 (43.4%) | ||
| Total | 4 (100.0%) | 76 (100.0%) | ||
| Metastasis | No distant metastasis (M0) | 3 (75.0%) | 54 (71.1%) | 0.675 |
| Distant metastasis present (M1) | 1 (25.0%) | 22 (28.9%) | ||
| Total | 4 (100.0%) | 76 (100.0%) | ||
| Histology | Adenocarcinoma | 0 (0.0%) | 4 (5.3%) | 0.843 |
| Squamous Cell Carcinoma | 4 (100.0%) | 70 (92.1%) | ||
| Other types | 0 (0.0%) | 2 (2.6%) | ||
| Total | 4 (100.0%) | 76 (100.0%) | ||
Patients Characteristics, histology, staging, treatment and outcome_
| Histology | n (%) | Total | |
|---|---|---|---|
| Squamous Cell Carcinoma | Squamous Cell Carcinoma | 67 (83.8%) | 74 (92.5%) |
| Moderately Differentiated Squamous Cell Carcinoma | 5 (6.3%) | ||
| Well-Differentiated Squamous Cell Carcinoma | 2 (2.5%) | ||
| Adenocarcinoma | Adenocarcinoma | 3 (3.8%) | 4 (5%) |
| Poorly Differentiated Adenocarcinoma | 1 (1.3%) | ||
| Other Types | High-Grade Neuroendocrine Carcinoma | 1 (1.3%) | 2 (2.5%) |
| Mucoepidermoid Carcinoma and Gastroesophageal Junction (GOJ) Tumor | 1 (1.3%) | ||
| Staging | |||
| T | Tumor invades lamina propria, muscularis mucosae, or submucosa (T1) | 1 (1.3%) | |
| Tumor invades muscularis propria (T2) | 16 (20%) | ||
| Tumor invades adventitia (T3) | 48 (60%) | ||
| Tumor invades adjacent structures (T4) | 15 (18.8%) | ||
| N | No regional lymph node metastasis (N0) | 12 (15%) | |
| Metastasis in 1–2 regional lymph nodes (N1) | 34 (42.5%) | ||
| Metastasis in 3–6 regional lymph nodes (N2) | 34 (42.5%) | ||
| M | No distant metastasis (M0) | 57 (71.3%) | |
| Distant metastasis present (M1) | 23 (28.7%) | ||
| Chemotherapy and Radiotherapy | |||
| No Chemotherapy or Radiotherapy | 11 (13.8%) | ||
| Combined Chemotherapy and Radiotherapy | 37 (46.3%) | ||
| Only Chemotherapy | 32 (40%) | ||
| Median duration of stent insertion to end date of the study | 83 days (min=1 day, max=7.24 yeras) | ||
| Survival status | |||
| Alive | 4 (5%) | ||
| Dead | 76 (95%) | ||